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Objective To explore the prescribing patterns of selective
serotonin reuptake inhibitors (SSRIs) before, during and after
pregnancy in six European population-based databases.
Design Descriptive drug utilisation study.
Setting Six electronic healthcare databases in Denmark, the
Netherlands, Italy (Emilia Romagna/Tuscany), Wales and the rest
of the UK.
Population All women with a pregnancy ending in a live or
stillbirth starting and ending between 2004 and 2010.
Methods A common protocol was implemented across databases
to identify SSRI prescriptions issued (UK) or dispensed
(non-UK) in the year before, during or in the year following
pregnancy.
Main outcome measures The percentage of deliveries in which
the woman received an SSRI prescription in the year before,
during or in the year following pregnancy. We also compared
the choice of SSRIs and changes in prescribing over the study
period.
Results In total, 721 632 women and 862 943 deliveries were
identified. In the year preceding pregnancy, the prevalence of
SSRI prescribing was highest in Wales [9.6%; 95% confidence
interval (CI95), 9.4–9.8%] and lowest in Emilia Romagna (3.3%;
CI95, 3.2–3.4%). During pregnancy, SSRI prescribing had
dropped to between 1.2% (CI95, 1.1–1.3%) in Emilia Romagna
and 4.5% (CI95, 4.3–4.6%) in Wales. The higher UK
pre-pregnancy prescribing rates resulted in higher first trimester
exposures. After pregnancy, SSRI prescribing increased most
rapidly in the UK. Paroxetine was more commonly prescribed in
the Netherlands and Italian regions than in Denmark and the
UK.
Conclusions The higher SSRI prescribing rates in the UK,
compared with other European regions, raise questions about
differences in the prevalence and severity of depression and its
management in pregnancy across Europe.
Keywords Drug utilisation, electronic health records, pregnancy,
serotonin uptake inhibitors.
Please cite this paper as: Charlton RA, Jordan S, Pierini A, Garne E, Neville AJ, Hansen AV, Gini R, Thayer D, Tingay K, Puccini A, Bos HJ, Nybo Andersen
AM, Sinclair M, Dolk H, de Jong-van den Berg LTW. Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a
population-based study in six European regions. BJOG 2014; DOI: 10.1111/1471-0528.13143.
Introduction
Depression is common among women of childbearing age,1
and the prevalence of depression affecting women during
pregnancy has been reported to range from 6% to 13%.2,3
Selective serotonin reuptake inhibitors (SSRIs) are the most
commonly prescribed class of antidepressant,4 and studies
evaluating patterns of prescribing have shown that between
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2.8%5 and 10.2%6 of women receive an SSRI prescription
at some point during pregnancy. The proportion of preg-
nant women prescribed or dispensed with an SSRI varies
by geographical location, study setting and calendar year,
with an increase in prescribing over time observed between
1995 and 2008.6–8
The effect of in utero SSRI exposure and exposure via
breast milk is incompletely understood; some, but not all,
observational studies have indicated that exposure during
pregnancy is associated with a number of adverse perinatal
and fetal outcomes.9–16 Untreated depression and treatment
discontinuation, however, are not without potential risks to
both the woman and the developing fetus.15,17 Complex
decisions therefore need to be made, by women and health-
care professionals, to balance the potential risks of fetal
exposure with the risks of no treatment or treatment dis-
continuation. As many pregnancies are unplanned,18 it is
important that women of childbearing age receive appro-
priate information when SSRI treatment is commenced.
The extent of SSRI prescribing during pregnancy has
been reported for some geographical regions, but for others
it is still unknown. To our knowledge, this is the first study
including pre- and post-pregnancy prescribing in multiple
areas of Europe. An understanding of variations in pre-
scribing patterns can inform the interpretation of potential
safety signals and identify areas requiring further research.
This study aims to describe the extent and nature of SSRI
prescribing to women before, during and after pregnancy
in six European population-based healthcare databases
between 2004 and 2010.
This study forms part of EUROmediCAT,19 a Seventh
Framework Programme study funded by the European
Union that aims to make more systematic use of electronic
healthcare databases in combination with EUROCAT20
congenital anomalies data.
Methods
Setting
Six population-based electronic healthcare databases, which
captured pregnancies and prescription data, contributed to
the study: two in Italy (Tuscany21 and Emilia Romagna22),
two in the UK [the Secure Anonymised Information Link-
age (SAIL) Databank in Wales23,24 and the UK-wide Clini-
cal Practice Research Datalink (CPRD)25 with data from
Wales excluded], one in Denmark26–28 and one in the
Netherlands29 (Table 1). A more detailed description of the
databases can be found elsewhere.30 Where multiple data-
bases were linked, such as in Denmark where the informa-
tion on all pregnancies from the Danish National Patient
Register was linked to the Danish National Prescription
Registry, for the remainder of this paper these linked data-
bases are referred to as a single database. Ethical and data
access approvals were obtained for each database from the
relevant governance infrastructures.
Data extraction
All databases followed a common protocol. Within each
database, all pregnancies starting and ending between 1
January 2004 and 31 December 2010 (except for Denmark,
where the final date was 31 December 2009) were identified
and the best estimate of the start of pregnancy was calcu-
lated. Pregnancies were eligible for the study if they ended
in a delivery (live birth or stillbirth) and the woman had
been present in the database, capturing prescription data,
during the entire year before pregnancy, throughout preg-
nancy and during the entire year following pregnancy. All
SSRI prescriptions recorded in the databases during the
time period of interest were identified. In the UK databas-
es, this included all SSRI prescriptions issued, whereas, in
the other databases, it included only SSRI prescriptions
actually dispensed. SSRIs were defined as products with an
Anatomical Therapeutic Chemical (ATC) code starting with
N06AB and included fluoxetine, citalopram, paroxetine,
sertraline, fluvoxamine and escitalopram.
Analyses
The percentage of women receiving (issued/dispensed) an
SSRI prescription in each of the databases was calculated
for the year leading up to pregnancy, during pregnancy
and for the year following pregnancy. Percentages were cal-
culated by dividing the number of deliveries in which the
woman received an SSRI prescription during the period of
interest by the total number of deliveries. Prescribing pat-
terns were described for each pregnancy trimester and for
3-month time periods during the years before and after
pregnancy. The choice of specific SSRI, co-prescribing of
antipsychotics, anxiolytics and hypnotics, and changes in
prescribing over calendar time were described and com-
pared.
Results
In the six databases, 721 632 eligible women with 862 943
deliveries were identified. The mean maternal age at the
start of pregnancy ranged from 27.7 years [standard devia-
tion (SD), 6.1] in Wales to 32.3 years (SD, 4.9) in Italy
(Emilia Romagna), and was significantly lower in Wales
than in other regions, including the rest of the UK
(CPRD)] (P < 0.001). Of all the deliveries, 5.4% [95% con-
fidence interval (CI95), 5.3–5.4%] of women received a pre-
scription for an SSRI during the year before pregnancy,
ranging from 3.3% (CI95, 3.2–3.4%) in Emilia Romagna to
9.6% (CI95, 9.4–9.8%) in Wales. During pregnancy, the
percentage of women receiving an SSRI prescription fell to
2.3% (CI95, 2.2–2.3%), ranging from 1.2% (CI95, 1.1–1.3%)
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in Emilia Romagna to 4.5% (CI95, 4.3–4.6%) in Wales
(Table 2).
SSRI prescribing during the year before and after preg-
nancy was considerably higher in both of the UK databases
compared with the Danish, Dutch and Italian databases
(Table 2). The higher pre-pregnancy rates in the UK
resulted in higher first trimester exposures. During the sec-
ond and third trimesters however, where SSRI prescribing
in all databases was at its lowest, the UK figures were in
line with those of Denmark and the Netherlands (Fig-
ure 1). After pregnancy, SSRI prescribing increased more
rapidly in the UK databases than in the others, and the
prevalence of use was considerably higher than that
pre-pregnancy. Outside the UK, by 6 months post-preg-
nancy, the prevalence of SSRI prescribing had returned to
pre-pregnancy levels (Figure 1).
Figure 2 shows the starting and stopping prescribing sce-
narios for women who received an SSRI prescription dur-
ing the year before pregnancy. Approximately 27% in the
Dutch and Danish databases continued to receive prescrip-
tions throughout pregnancy and during the year following
pregnancy, compared with 10–12% in the UK databases
and 4–9% in the Italian databases (Figure 2). Approxi-
mately 40% of women in the Dutch, Danish and UK data-
bases stopped SSRI treatment before pregnancy and did
not receive an SSRI prescription during pregnancy or in
the year following delivery; in Italy, this percentage was
higher at 56% in Tuscany and 67% in Emilia Romagna
(Figure 2). In the UK databases, a further 25% discontin-
ued before pregnancy, but restarted during the year after
pregnancy; outside the UK, this scenario ranged from
10.8% to 14.6% of women. Women who discontinued SSRI
use before pregnancy were quicker to restart following
delivery in the UK and the Netherlands than in Italy and
Denmark, with around 45% and 30% of the restarters,
respectively, doing so within 3 months of delivery (data
not shown). Overall, 0.5% (CI95, 0.5–0.6%) of women
received their first SSRI prescription during pregnancy,
having not received a prescription during the year before
pregnancy, ranging from 0.3% (CI95, 0.2–0.4%) in the
Netherlands to 1.0% (CI95, 0.9–1.1%) in Wales (data not
shown).
Between 2004 and 2009, a steady increase was observed
in the percentage of deliveries in which the woman
received a prescription for an SSRI during any of the preg-
nancy trimesters in Denmark, whereas smaller increases
were observed in the UK databases (Figure 3). Fluoxetine
and citalopram were the SSRIs of choice during pregnancy
in Denmark and the UK databases, whereas, in Italy and
the Netherlands, paroxetine was more popular (Figure 4).
There was a steady increase in the use of citalopram and
sertraline in the UK and Denmark during the study period
and a slight decline in paroxetine (data not shown). All
other prescribing remained relatively constant over time.
Levels of co-prescribing of products that act on the cen-
tral nervous system were found to be higher in the Dutch
database than in those of the UK and Denmark, particu-
larly for anxiolytics (Supporting Information Figure S1). In
the Danish and UK databases, levels of co-prescribing of
anxiolytics and hypnotics/sedatives were similar pre- and
post-pregnancy (between 4% and 6% of those receiving a
prescription for an SSRI) with a small decline during the
three pregnancy trimesters. Data on the co-prescribing of
antipsychotics in Italy are likely to have underestimated
Table 2. Percentage of deliveries in the period 2004–2010 in which the woman received a prescription for a selective serotonin reuptake
inhibitor (SSRI) in the year before pregnancy, during pregnancy or in the year following pregnancy
Country/region Number of eligible
deliveries in entire
cohort
Mean maternal age
at pregnancy start for
entire cohort
SSRI prescription during:
The year
before
pregnancy
Any of the
pregnancy
trimesters
The year
following
pregnancy
n Years (SD*) % 95% CI % 95% CI % 95% CI
The Netherlands 13 935 29.4 (4.8) 3.9 3.6–4.2 2.3 2.0–2.5 4.3 4.0–4.6
Denmark** 320 846 30.0 (4.9) 4.1 4.0–4.1 2.3 2.3–2.4 4.1 4.0–4.2
Italy: Emilia Romagna 129 220 32.3 (4.9) 3.3 3.2–3.4 1.2 1.1–1.3 2.5 2.4–2.6
Italy: Tuscany 157 916 31.8 (4.9) 4.4 4.3–4.5 1.6 1.5–1.7 3.4 3.3–3.5
UK*** 182 920 30.2 (6.1) 8.8 8.6–8.9 3.7 3.6–3.8 12.9 12.7–13.0
Wales 58 106 27.7 (6.1) 9.6 9.4–9.8 4.5 4.3–4.6 15.0 14.7–15.3
*Standard deviation.
**2004–2009.
***Excluding Wales to avoid duplication of pregnancies in the Secure Anonymised Information Linkage (SAIL) databank.
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Figure 1. Percentage of all deliveries between 2004 and 2010 in which the woman received a prescription for a selective serotonin reuptake
inhibitor (SSRI) during one or more of the time periods of interest. *Excluding Wales.
Figure 2. Starting and stopping scenarios for deliveries in which the mother had a selective serotonin reuptake inhibitor (SSRI) prescription during
the year before pregnancy.
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Figure 3. Percentage of deliveries in which the woman had a prescription for a selective serotonin reuptake inhibitor (SSRI) during any of the
pregnancy trimesters by calendar year. *Excluding Wales.
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actual use, as some of the products available are not reim-
bursed by the Italian health service and therefore escape
recording. No data were available on the co-prescribing of
anxiolytics and hypnotics/sedatives in Italy as these drugs
are not reimbursed by the Italian health service.
Discussion
Main findings
Across Europe, marked differences appear to exist in the
extent of SSRI prescribing to women before, during and
after pregnancy, although these differences may be magni-
fied by the UK databases recording prescriptions issued
and the non-UK databases recording prescriptions dis-
pensed. The prescribing of SSRIs was considerably higher
in both UK databases than in the Danish, Dutch and Ital-
ian databases. In all databases, SSRI prescribing was at its
lowest during the second and third trimesters of pregnancy.
At least 40% of those with a prescription during the year
preceding pregnancy discontinued before pregnancy and
did not restart during the year following delivery. Of those
who received a prescription in the year before pregnancy,
the Danish and Dutch databases had the highest percentage
of women continuing SSRI treatment throughout preg-
nancy and following delivery, and the Italian databases had
the lowest. Differences were observed in terms of the most
commonly prescribed SSRIs during pregnancy.
Strengths and limitations
This study captured over 850 000 pregnancies in six differ-
ent areas of Europe. SSRI prescribing was recorded inde-
pendently by the prescriber or pharmacist, and so
ascertainment was not reliant on maternal involvement,
which can result in potential recall and selection biases.31,32
The shared data extraction protocol ensured that the study
results were as comparable as possible across databases.
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Figure 4. Percentage of all deliveries between 2004 and 2010 in which the woman received a prescription for the individual selective serotonin
reuptake inhibitor (SSRI) during any of the pregnancy trimesters. *Excluding Wales.
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However, differences did exist between healthcare systems
and the type of data available for research. Data in the UK
databases were based on prescriptions issued, whereas, in
Denmark, the Netherlands and Italy, data were based on
prescriptions dispensed by a pharmacist. Some women who
receive prescriptions for antidepressants choose not to
redeem them from the pharmacist33 and this may explain
some, but not all, of the difference between the UK data-
bases and other regions. The rate of prescription redemp-
tion is difficult to quantify and likely to vary by region,
study population, type of drug and even a life event such
as pregnancy. A study carried out in the UK in the late
1980s, looking at prescription redemption for all medi-
cines,34 found young women to be particularly poor
redeemers, with 27.6% of women aged 16–29 years not
redeeming their prescriptions; it is unclear whether this is
still the case and whether it applies specifically to SSRIs.
Studies of antidepressant prescription redemption have
reported rates ranging from 78.6% in the USA35 to 95.8%
in the Netherlands, where 23.7% redeemed only a single
prescription.33 However, even if we conservatively assume
that 25% of prescriptions in the UK are not redeemed, the
differences observed in our study are much larger than
this.
In the UK, the GP is the main source of SSRI prescrib-
ing, whereas, in other European countries, a hospital spe-
cialist may be more likely to prescribe directly to the
patient. In Denmark and the Netherlands, all SSRI pre-
scriptions were captured, with the exception of those issued
during a hospital stay. Although prescriptions issued during
a hospital stay, prescriptions initiated by a specialist in a
hospital outpatient department and private prescriptions
were rarely recorded in the UK databases, the numbers
were likely to be small. In Italy, prescriptions issued pri-
vately or by a specialist which were dispensed at a hospital
pharmacy were not captured; based on data from Emilia
Romagna for 2010–2011, when these data are included in
the database, hospital prescriptions are thought to represent
approximately 10% of all SSRI prescribing (A. Puccini,
pers. comm.).
In three databases, it was necessary to estimate, for some
pregnancies, the duration of pregnancy and the date of the
last menstrual period (see Table 1 for details), and this
may have resulted in some exposure status misclassifica-
tion. Our figures are based on women who received a pre-
scription for an SSRI during 11 3-month time periods, and
we do not know whether they actually took the product or
took it as instructed. In addition, this study did not
account for prescriptions issued during one 3-month time
period which could have continued to be consumed during
the following 3-month time period, and this will have
resulted in an underestimation of exposure during some
time periods.
This study did not examine the prevalence of depression
or the use of other antidepressants. Therefore, the findings
do not reflect the full extent to which women are exposed to
antidepressants before, during and after pregnancy. It is pos-
sible that the higher levels of SSRI prescribing in the UK/
Wales could be explained in part by SSRIs making up a larger
percentage of all antidepressant prescribing in the UK than
in the other regions, but it was not possible to look at this as
part of this study. However, current UK prescribing guide-
lines advise that tricyclic antidepressants are safer than other
antidepressants in pregnancy.36 This study did not examine
the indications for prescribing; SSRIs are indicated for a
range of conditions in addition to depression, and these may
vary between regions. No data were available on the appro-
priateness of use or efficacy of the SSRIs used.
Comparison with other studies
The percentages of women receiving prescriptions for SSRIs
during pregnancy in the areas captured by this study corre-
spond well with other studies for the UK as a whole37 and
for the Netherlands.8,38 In Denmark, the steady increase in
SSRI prescribing during the study period was in line with
the increase in SSRI prescribing reported for the general
population during a similar study period in Denmark.39
However, it is not clear whether this trend has continued
after 2009. To our knowledge, this is the first study to look
at the extent of SSRI prescribing during pregnancy in an
Italian population. Prescribing of SSRIs during pregnancy
in all European databases was lower than in the
USA,6,7,40,41 where studies have reported percentages of
between 5.6%40 and 10.2%,6 depending on the years of
study and the study setting. The proportions of women
receiving prescriptions for SSRIs during the first trimester
of pregnancy in the UK were similar to those reported for
Australia9 and Canada.42
Interpretation
Other than methodological factors, difference in prescribing
may reflect differences in the prevalence of depression, in
the severity of depression, in help-seeking behaviour or in
prescribing behaviour at national and subnational level.
Although the two UK databases both collected data on pre-
scriptions issued, higher levels of SSRI prescribing to
women were observed in Wales than in the rest of the UK.
This may reflect the higher number of antidepressants pre-
scribed per capita in Wales,43 and the lower socioeconomic
status and per capita income in Wales44 may also explain
in part the discrepancies in prescribing. Regional differ-
ences were also observed in Italy, with a lower percentage
of females receiving a prescription for an SSRI in Emilia
Romagna than in Tuscany; however, this appears to be in
line with regional SSRI prescribing differences observed for
the general population.45
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The popularity of paroxetine in Italy and the Netherlands
and the absence of a reduction in its prescribing over the
study period are surprising, given the number of studies that
have demonstrated an increase in the risk of congenital heart
defects associated with paroxetine exposure during the early
stages of pregnancy.9,12,46 In the Netherlands, new guidelines
on the prescribing of SSRIs during pregnancy were issued in
2012, after the end of our study period; these do not specify
a preferred SSRI, but do recommend that, if paroxetine is
taken during the periconceptional period, the dose should
not exceed 20 mg/day.47 In Italy, an official safety note was
issued by the Italian Medicine Agency in February 200648
and, in November 2010, at the end of the study period, a rec-
ommendation was issued by the Agency’s Paediatric Work-
ing Group suggesting that paroxetine should only be used
when strictly indicated.49 UK guidelines recommend that, if
a woman taking paroxetine is planning a pregnancy or has
an unplanned pregnancy, she should be advised to stop tak-
ing the drug and advised that fluoxetine is the SSRI with the
lowest known risk during pregnancy,36 concording with fluo-
xetine being one of the most popular SSRIs in the UK in our
study. The steady increase in the use of citalopram and sertr-
aline during the study period in Denmark and the slight
decline in paroxetine correspond to changes to the prescrib-
ing guidelines.50
When a woman becomes pregnant, the risk–benefit pro-
file of SSRI medication changes, and this is evident from
the reduction in SSRI use observed in all European
regions during the first trimester of pregnancy, and the
further reduction during the second and third trimesters.
The efficacy of antidepressant treatment in less than severe
depression has been questioned,51 suggesting a negative
benefit–risk balance, except for severe depression. Prescrib-
ing guidelines in the UK currently recommend that preg-
nant women with mild depression should have their
medication withdrawn and replaced by self-help or psy-
chological treatments.36 Further research should investigate
whether women with mild depression are being inappro-
priately prescribed antidepressants during pregnancy,
deriving no established benefit, but exposing the fetus to
possible risk. Equally important, however, for both mother
and baby, is to ensure that depression does not go
untreated, that psychological therapies are available where
needed and that any discontinuation of SSRI treatment is
carried out in a controlled manner. We were not able to
establish whether the high rates of discontinuation before
and during pregnancy in Europe reflect controlled discon-
tinuation for women who are offered alternative treat-
ments or no longer require treatment, or represent unmet
needs and greater levels of depression-related risk among
pregnant women.
In Denmark and the Netherlands, a much larger propor-
tion of women using SSRIs before pregnancy continued to
receive prescriptions during and after pregnancy compared
with the other European regions. This might reflect a more
relaxed attitude to SSRI use during pregnancy in Denmark
and the Netherlands, but, given the lower percentage of
women receiving an SSRI at any time during the study per-
iod, it is likely that, in these countries, a larger proportion
of women receiving SSRIs have a medical condition suffi-
ciently severe to warrant continuation. The differences
observed in postnatal prescribing and the point at which
women who had discontinued treatment restarted following
delivery may be related in part to differences in the rates of
breastfeeding. The percentage of mothers breastfeeding to
any extent at 6 weeks post partum has been reported to be
approximately 55% in the UK as a whole and 40% in
Wales,52 whereas, in Italy, 49% of mothers are still breast-
feeding 3 months after delivery53 and, in Denmark, 60%
are breastfeeding at 4 months post-delivery.54 The impact
of UK guidelines recommending case identification for
postnatal depression at 4–6 weeks and 3–4 months
post-pregnancy36 is uncertain, but may have contributed to
the higher SSRI prescribing rates observed. Postnatal
screening for depression was not routinely carried out in
the Netherlands, Italy or Denmark during the study period
and, following a policy review in 2011, screening for post-
natal depression is no longer recommended in the UK.55
Conclusion
The considerably higher levels of SSRI prescribing observed
in the UK databases compared with other European data-
bases raises questions about differences in the prevalence
and severity of depression and its management in preg-
nancy across Europe. The variations observed in the type
and extent of SSRI prescribing indicate an absence of Euro-
pean consensus on prescribing to pregnant women and
women of childbearing age. Further work is required to
understand the reasons for the higher levels of SSRI pre-
scribing observed in the UK databases, and the extent to
which these reflect medical need and endemic prescribing
patterns. Further work is required to better understand the
potential adverse fetal and child outcomes following SSRI
exposure, and this is the focus of the current EUROmedi-
CAT project.19
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